CoChat

Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function.

Published version of a preprint

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Abstract

Targeted therapy against the BRAF/mitogen-activated protein kinase (MAPK) pathway is a promising new therapeutic approach for the treatment of melanoma. Treatment with selective BRAF inhibitors results in a high initial response rate but limited duration of response. To counter this, investigators propose combining this therapy with other targeted agents, addressing the issue of redundancy and signaling through different oncogenic pathways. An alternative approach is combining BRAF/MAPK-targeted agents with immunotherapy. Preliminary evidence suggests that oncogenic BRAF (BRAFV600E) contributes to immune escape and that blocking its activity via MAPK pathway inhibition leads to increased expression of melanocyte differentiation antigens (MDA). Recognition of MDAs is a critical component of the immunologic response to melanoma, and several forms of immunotherapy capitalize on this recognition. Among the various approaches to inhibiting BRAF/MAPK, broad MAPK pathway inhibition may have deleterious effects on T lymphocyte function. Here, we corroborate the role of oncogenic BRAF in immune evasion by melanoma cells through suppression of MDAs. We show that inhibition of the MAPK pathway with MAPK/extracellular signal-regulated kinase kinase (MEK) inhibitors or a specific inhibitor of BRAFV600E in melanoma cell lines and tumor digests results in increased levels of MDAs, which is associated with improved recognition by antigen-specific T lymphocytes. However, treatment with MEK inhibitors impairs T lymphocyte function, whereas T-cell function is preserved after treatment with a specific inhibitor of BRAFV600E. These findings suggest that immune evasion of melanomas mediated by oncogenic BRAF may be reversed by targeted BRAF inhibition without compromising T-cell function. These findings have important implications for combined kinase-targeted therapy plus immunotherapy for melanoma. Cancer Res; 70(13); 5213–9. ©2010 AACR.

Overview

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-10-0118

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 21 references

Cited by

See all 754

Metadata

Authors
Boni, A., Cogdill, A. P., Dang, P., Udayakumar, D., Njauw, C.-N. J., Sloss, C. M., Ferrone, C. R., Flaherty, K. T., Lawrence, D. P., Fisher, D. E., Tsao, H., & Wargo, J. A.
Affiliations
Harvard University (US)
Venue
Cancer Research
Published
2010-06-30
Volume
70
Issue
13
Pages
5213-5219
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2116376943
Cited by
742
References
21
Citations by year
2026: 15 · 2025: 13 · 2024: 14 · 2023: 50 · 2022: 41 · 2021: 40 · 2020: 53 · 2019: 40 · 2018: 39 · 2017: 60 · 2016: 49 · 2015: 60 · 2014: 73 · 2013: 95 · 2012: 51
FWCI
25.16
Type
journal article
Language
en
Open access
closed
Locations
  • Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Massachusetts General Hospital
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR043369)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
BRAF V600E mutation, melanoma, MAPK inhibition, MEK inhibitors, melanocyte differentiation antigens, T cell recognition, immune evasion, T lymphocyte function, targeted therapy, immunotherapy, combination therapy
MeSH terms
Antigens, Neoplasm, Benzamides, Butadienes, Combined Modality Therapy, Diphenylamine, Humans, Melanoma, Membrane Glycoproteins, Neoplasm Proteins, Nitriles, Oxidoreductases, T-Lymphocytes, Epitopes, T-Lymphocyte, Intramolecular Oxidoreductases, MAP Kinase Signaling System, Cell Line, Tumor, Extracellular Signal-Regulated MAP Kinases, Proto-Oncogene Proteins B-raf, gp100 Melanoma Antigen, MART-1 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. https://app.cochat.ai/papers/10.1158/0008-5472.can-10-0118
The paper
Boni, A., Cogdill, A. P., Dang, P., Udayakumar, D., Njauw, C.-N. J., Sloss, C. M., Ferrone, C. R., Flaherty, K. T., Lawrence, D. P., Fisher, D. E., Tsao, H., & Wargo, J. A. (2010). Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Research. https://doi.org/10.1158/0008-5472.can-10-0118

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.